Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00002064
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service

Brief Summary:
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Condition or disease Intervention/treatment Phase
Toxoplasmosis, Cerebral HIV Infections Drug: Pyrimethamine Drug: Clindamycin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Encephalitis





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions are excluded:

  • Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.

Patients with other opportunistic infections or brain diseases are excluded.

Patients with AIDS and cerebral toxoplasmosis.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002064


Locations
Layout table for location information
United States, California
Palo Alto Med Foundation
Palo Alto, California, United States, 94301
Sponsors and Collaborators
Palo Alto Medical Foundation

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00002064     History of Changes
Other Study ID Numbers: 021A
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: June 1989
Keywords provided by NIH AIDS Clinical Trials Information Service:
Sulfonamides
Toxoplasmosis
AIDS-Related Opportunistic Infections
Pyrimethamine
Drug Therapy, Combination
Encephalitis
Acquired Immunodeficiency Syndrome
Clindamycin
Additional relevant MeSH terms:
Layout table for MeSH terms
Toxoplasmosis, Cerebral
Toxoplasmosis
Encephalitis
Infection
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Coccidiosis
Protozoan Infections
Parasitic Diseases
Brain Abscess
Abscess
Suppuration
Central Nervous System Protozoal Infections
Central Nervous System Parasitic Infections
Central Nervous System Infections
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Pyrimethamine
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Folic Acid Antagonists